Attached files

file filename
EX-5.1 - OPINION OF DLA PIPER LLP (US) - GenMark Diagnostics, Inc.dex51.htm
EX-23.3 - CONSENT OF DELOITTE LLP (UK) - GenMark Diagnostics, Inc.dex233.htm
EX-23.2 - CONSENT OF DELOITTE & TOUCHE LLP (US) - GenMark Diagnostics, Inc.dex232.htm

As filed with the Securities and Exchange Commission on June 17, 2011

Registration No. 333-            

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

GenMark Diagnostics, Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   3841   27-2053069

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

5964 La Place Court

Carlsbad, CA 92008

(760) 448-4300

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

 

Hany Massarany

President and Chief Executive Officer

GenMark Diagnostics, Inc.

5964 La Place Court

Carlsbad, CA 92008

(760) 448-4300

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

 

Michael S. Kagnoff, Esq.

DLA Piper LLP (US)

4365 Executive Drive, Suite 1100

San Diego, CA 92121

Tel: (858) 677-1400

Fax: (858) 677-1401

 

Timothy R. Curry, Esq.

Jones Day

1755 Embarcadero Road

Palo Alto, CA 94303

Tel: (650) 739-3939

Fax: (650) 739-3900

 

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.  ¨

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  x  333-174524

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ¨

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one):

 

Large accelerated filer   ¨    Accelerated filer   ¨
Non-accelerated filer   x  (Do not check if a smaller reporting company)    Smaller reporting company   ¨

 

 

CALCULATION OF REGISTRATION FEE

 

 
Title of Each Class of
Securities to be Registered
 

Proposed

Maximum
Aggregate

Offering
Price(1)

  Amount of
Registration Fee

Common Stock, $0.0001 par value per share

  $5,755,520   $669
 
 

 

(1) Includes the additional shares of common stock that are issuable upon exercise of the underwriters’ over-allotment option.

The registration statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) under the Securities Act of 1933 as amended.

 

 

 


EXPLANATORY NOTE

This registration statement is being filed with respect to the registration of additional shares of common stock of GenMark Diagnostics, Inc., a Delaware corporation, pursuant to Rule 462(b) under the Securities Act of 1933, as amended. The contents of the registration statement on Form S-1 (Registration No. 333-174524), initially filed by GenMark with the Securities and Exchange Commission on May 26, 2011, as amended by Amendment No. 1 thereto filed on June 8, 2011, and which was declared effective on June 16, 2011, including the exhibits thereto, are incorporated herein by reference.

The required opinions and consents are listed on an Exhibit Index attached hereto and filed herewith.


PART II.

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 16. Exhibits

All exhibits filed with or incorporated by reference in Registration Statement No. 333-174524 are incorporated by reference into, and shall be deemed a part of this Registration Statement, except the following which are filed herewith:

 

Exhibit

Number

  

Description

  5.1    Opinion of DLA Piper LLP (US)
23.1    Consent of DLA Piper LLP (US) (included in Exhibit 5.1)
23.2    Consent of Deloitte & Touche LLP (US)
23.3    Consent of Deloitte LLP (UK)
24.1   

Power of Attorney (incorporated by reference to the signature page included with the Registration Statement on

Form S-1 of the Registrant (File No. 333-174524)).

 

II-1


SIGNATURES

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Carlsbad, California, on June 17, 2011.

 

GENMARK DIAGNOSTICS, INC.
By:  

/s/    HANY MASSARANY        

  Name: Hany Massarany
  Title: President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated below.

 

Signature

  

Title

 

Date

/s/    Hany Massarany

Hany Massarany

  

President and Chief Executive Officer (Principal
Executive Officer)

  June 17, 2011

/s/    Paul Ross

Paul Ross

  

Chief Financial Officer (Principal Financial Officer
and Principal Accounting Officer)

  June 17, 2011

*

Christopher Gleeson

   Chairman of the Board   June 17, 2011

*

Daryl J. Faulkner

   Director   June 17, 2011

*

Jim Fox

   Director   June 17, 2011

*

Kevin C. O’Boyle

   Director   June 17, 2011

 

*By:  

/S/    Hany Massarany        

   

Hany Massarany

Attorney-in-fact

 

 

II-2